India, Nov. 6 -- The healthcare sector saw a busy week, with several companies securing regulatory approvals, announcing workforce restructuring, and advancing strategic business deals.
On the regulatory front, Dr. Reddy's Laboratories secured Brazil approval for generic semaglutide and tentative FDA approval for its twice-yearly HIV prevention shot, while Lupin and Sun Pharma received FDA approvals for generic Firdapse and Ilumya, respectively.
Meanwhile, Agios and Ultragenyx announced significant workforce cuts as part of cost-reduction efforts, while CVS Health unveiled plans to separate into two publicly traded companies. Deal activity also included licensing agreements, strategic collaborations, and acquisitions across the healthcare...